Norway’s Nykode Therapeutics is coming to terms with Roche’s surprise decision earlier this month to end the firms' cancer vaccine partnership, with significant job losses an inevitable consequence.
The Oslo-headquartered group was stunned when Roche’s Genentech subsidiary said on 7 November that it would be pulling out of...